murepavadin cas: 944252-63-5

CAS NO: 944252-63-5
murepavadin
Chemical Name: murepavadin
Molecular Formula: C73H112N22O16
Formula Weight: 1553.84
CAS No.: 944252-63-5
Description Review
Description

Murepavadin is a novel antibiotic that targets Pseudomonas aeruginosa, a bacteria commonly found in hospitals and known for its resistance to many antibiotics. It is used in the treatment of respiratory infections and has shown promising results in clinical trials. In this article, we will discuss the chemical and physical properties of murepavadin, its health benefits, potential effects, product mechanism, safety, side effects, dosing information, and conclusion.

Chemical Name (3R,6S,9S,12R,15S,18S,21S,24S,30S,33S)-33-(((2S)-4-carbamimidamidobutanamido)methyl)-12-(1H-imidazol-5-ylmethyl)-9,15,18,24-tetraisobutyl-21-(2-methyl-2-propanyl)-6-(2-methylbutanoyl)-3,30-dioxa-24-azahexatriacontan-36-oic acid

Molecular Formula C62H99N11O8

Formula Weight 1121.58 g/mol

CAS No 944252-63-5

Top Ten Keywords from Google

  1. Murepavadin
  2. Antibiotic
  3. Pseudomonas aeruginosa
  4. Respiratory infections
  5. Antibiotic resistance
  6. Gram-negative bacteria
  7. Clinical trials
  8. Peptide therapy
  9. Drug interactions
  10. Mechanism of action

Synonyms

  • POL7080
  • LYS228

Health Benefits of this Product Murepavadin has a number of potential health benefits due to its ability to target Pseudomonas aeruginosa, a bacteria known for its resistance to many antibiotics. Some of the most important health benefits of this compound include:

  1. Treatment of respiratory infections: Murepavadin is primarily used for the treatment of respiratory infections caused by Pseudomonas aeruginosa.

  2. Antibiotic resistance prevention: Murepavadin may help prevent the development of antibiotic resistance by targeting bacteria in a different way than other antibiotics.

Potential Effects The potential effects of murepavadin are numerous and varied. Some of the most notable effects of this compound include:

  1. Targeting Pseudomonas aeruginosa: Murepavadin targets Pseudomonas aeruginosa, a bacteria known for its resistance to many antibiotics.

  2. Selective action: Murepavadin selectively targets Pseudomonas aeruginosa, leaving other bacteria unharmed.

Product Mechanism Murepavadin works by binding to the outer membrane protein F (OprF) of Pseudomonas aeruginosa, a protein that is essential for the bacteria's survival. By binding to OprF, murepavadin disrupts the integrity of the bacterial cell wall, leading to the death of the bacteria.

Safety Murepavadin is generally considered to be safe when used as directed. However, like all medications, it can cause side effects in some people. It is important to discuss the risks and benefits of using murepavadin with your healthcare provider before starting treatment.

Side Effects Some of the most common side effects of murepavadin include headache, nausea, and diarrhea. Other possible side effects include allergic reactions, liver toxicity, and changes in kidney function. If you experience any of these side effects, it is important to contact your healthcare provider immediately.

Dosing Information The dose of murepavadin will vary depending on the individual and the condition being treated. It is important to follow the dosing instructions provided by your healthcare provider.

Conclusion In conclusion, murepavadin is a promising new antibiotic that targets Pseudomonas aeruginosa, a bacteria known for its resistance to many antibiotics. Its ability to selectively target this bacteria may help prevent the development of antibiotic resistance. However, like all medications, it can cause side effects in some people, and it is important to discuss the risks and benefits of using it with your healthcare provider before starting treatment. Despite some possible side effects, murepavadin is a valuable new tool in the fight against antibiotic-resistant bacteria and may help improve outcomes for patients with respiratory infections caused by Pseudomonas aeruginosa.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code